SHMT1
Serine hydroxymethyltransferase, cytosolic
Protein Summary
Interconversion of serine and glycine (PubMed:8505317, PubMed:24698160). This gene encodes the cytosolic form of serine hydroxymethyltransferase, a pyridoxal phosphate-containing enzyme that catalyzes the reversible conversion of serine and tetrahydrofolate to glycine and 5,10-methylene tetrahydrofolate. This reaction provides one-carbon units for synthesis of methionine, thymidylate, and purines in the cytoplasm. This gene is located within the Smith-Magenis syndrome region on chromosome 17. A pseudogene of this gene is located on the short arm of chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
- ENST00000316694
- ENSP00000318868
- ENSG00000176974
- ENST00000352886
- ENSP00000345881
- ENST00000354098
- ENSP00000318805
- SHMT
- CSHMT
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 1 | ||
transcription factor perturbation | 0.88 | ||
molecular function | 0.86 | ||
interacting protein | 0.77 | ||
tissue sample | 0.76 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 519.53 (req: < 5)
Gene RIFs: 72 (req: <= 3)
Antibodies: 244 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 519.53 (req: >= 5)
Gene RIFs: 72 (req: > 3)
Antibodies: 244 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 27
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0